TORONTO– CIBC Innovation Banking announced today that it has provided credit facilities to support MediSpend’s acquisition of Real Life Sciences (“RLS”), a leading provider of advanced anonymization and redaction solutions for clinical trial data. Backed by Susquehanna Growth Equity (“SGE”), MediSpend provides commercial compliance solutions for the largest pharmaceutical, medical device and dental companies as well as emerging biotech companies across the world.
“CIBC Innovation Banking has been a great to work with over the years and having a collaborative relationship is critical,” said Leigh Powell, Executive Chairman of MediSpend. “By working with CIBC Innovation Banking to complete the acquisition of Real Life Sciences, we are able to expand our product suite into R&D around clinical trial data compliance and create a comprehensive GRC platform to continue to support our life sciences customers.”
“We are thrilled to support SGE and the MediSpend team in the acquisition of RLS, enabling the company to deliver cutting-edge solutions that ensure compliance, protect participant privacy, and drive transparency in clinical trials,” said Oleg Dudchenko, Executive Director, CIBC Innovation Banking. “This strategic move underscores MediSpend’s commitment to advancing compliance and transparency in the life of sciences sector.”
